Data from the OPTIMISE study examined whether cannabis use triggers symptomatic relapse in first-episode schizophrenia or whether relapse leads to increased cannabis use.
Psychiatrists managing early psychosis, patients with schizophrenia, and researchers studying cannabis-psychosis interactions.
Trigger or consequence?Study examines whether cannabis drives relapse or relapse drives cannabis use in first-episode schizophrenia
What the researchers found
The analysis examined the temporal relationship between cannabis use, antipsychotic compliance, and relapse risk in first-episode schizophrenia patients in remission, addressing whether cannabis is a trigger or consequence of symptom recurrence.
Why it matters
Understanding the direction of the cannabis-relapse relationship is critical for clinical management: if cannabis triggers relapse, prevention efforts should focus on abstinence; if relapse drives cannabis use, underlying symptoms need better management.
The numbers in context
Data from the OPTIMISE study, a large European study on first-episode schizophrenia, schizophreniform, or schizoaffective disorder patients in remission.
How the study worked
Secondary analysis of the OPTIMISE European multicenter study examining temporal relationships between cannabis use and symptomatic relapse.
Who was studied
Patients in remission following a first episode of schizophrenia, schizophreniform, or schizoaffective disorder across European sites.
What this study cannot tell us
Observational analysis within a clinical trial; self-reported cannabis use; complex temporal relationships are difficult to disentangle even with longitudinal data.
How to read the evidence
Secondary analysis from large European multicenter study; longitudinal data allows temporal analysis but cannot prove causation.
When this study was published
Recent analysis from an ongoing first-episode psychosis research program.
The bigger picture
The trigger-vs-consequence question has major implications for clinical guidelines on cannabis counseling in early psychosis and for understanding whether cannabis cessation should be a treatment priority.
Replication
Contributes to the broader debate on cannabis and psychosis directionality; OPTIMISE provides uniquely detailed first-episode data.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- Does cannabis use precede relapse or follow prodromal symptoms?
- Does antipsychotic non-compliance mediate the cannabis-relapse relationship?
- Would different cannabis products carry different relapse risk?
Read the original research
Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study.
Schizophrenia bulletin, 49(4), 903-913
Citation
Levi, Linda; Bar-Haim, Mor; Winter-van Rossum, Inge; Davidson, Michael; Leucht, Stefan; Fleischhacker, Wolfgang W; Park, Jinyoung; Davis, John M; Kahn, Renè S; Weiser, Mark. (2023). Cannabis Use and Symptomatic Relapse in First Episode Schizophrenia: Trigger or Consequence? Data From the OPTIMISE Study.. Schizophrenia bulletin, 49(4), 903-913. https://doi.org/10.1093/schbul/sbad033